Physician profile
David B Dye
NPI 1437192903
$8,876.63
in general payments reported to CMS, 2019-2025
42 companies · $1,702 in 2025
The $1,702 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $728 · 2020: $898 · 2021: $910 · 2022: $1,239 · 2023: $1,624 · 2024: $1,776 · 2025: $1,702.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,896 · Education: $205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,896.32 |
| Education | $205.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,093.83 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $997.72 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $982.03 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $715.42 | 2019-2025 | |
| Abbvie INC. | $568.35 | 2021-2025 | Ubrelvy, Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $458.01 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $449.76 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $430.96 | 2021-2025 | Evenity, Prolia, Repatha |
| Sanofi-Aventis U.S. LLC | $390.29 | 2021-2023 | |
| Astellas Pharma US INC | $364.91 | 2022-2024 | Veozah, Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $334.03 | 2019-2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $327.27 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $222.74 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Sumitomo Pharma America, INC. | $165.95 | 2023-2025 | Gemtesa |
| Sunovion Pharmaceuticals INC. | $156.32 | 2019-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Dye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.